These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 29474302)
1. ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: An Independent Analysis of Protocol i Study Data. Dugel PU; Campbell JH; Kiss S; Loewenstein A; Shih V; Xu X; Holekamp NM; Augustin AJ; Ho AC; Gonzalez VH; Whitcup SM Retina; 2019 Jan; 39(1):88-97. PubMed ID: 29474302 [TBL] [Abstract][Full Text] [Related]
2. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. Gonzalez VH; Campbell J; Holekamp NM; Kiss S; Loewenstein A; Augustin AJ; Ma J; Ho AC; Patel V; Whitcup SM; Dugel PU Am J Ophthalmol; 2016 Dec; 172():72-79. PubMed ID: 27644589 [TBL] [Abstract][Full Text] [Related]
3. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial. Song S; Yu X; Zhang P; Gu X; Dai H BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639 [TBL] [Abstract][Full Text] [Related]
4. Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study. Karst SG; Deak GG; Gerendas BS; Waldstein SM; Lammer J; Simader C; Guerin T; Schmidt-Erfurth UM JAMA Ophthalmol; 2018 Apr; 136(4):315-321. PubMed ID: 29494727 [TBL] [Abstract][Full Text] [Related]
5. Early Response to Ranibizumab Is Associated with 12-Month Outcome in Diabetic Macular Edema after Prior Macular Laser Therapy. Sheu SJ; Lee YY Ophthalmologica; 2017; 238(3):139-146. PubMed ID: 28715811 [TBL] [Abstract][Full Text] [Related]
6. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA. Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550 [TBL] [Abstract][Full Text] [Related]
7. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM; Am J Ophthalmol; 2019 Jun; 202():91-99. PubMed ID: 30771333 [TBL] [Abstract][Full Text] [Related]
8. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines. Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306 [TBL] [Abstract][Full Text] [Related]
9. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment. Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605 [TBL] [Abstract][Full Text] [Related]
10. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK; JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949 [TBL] [Abstract][Full Text] [Related]
11. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema. Gerendas BS; Prager S; Deak G; Simader C; Lammer J; Waldstein SM; Guerin T; Kundi M; Schmidt-Erfurth UM Br J Ophthalmol; 2018 Feb; 102(2):195-203. PubMed ID: 28724636 [TBL] [Abstract][Full Text] [Related]
12. Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation. Hirano T; Toriyama Y; Iesato Y; Imai A; Hirabayashi K; Nagaoka T; Takamura Y; Sugimoto M; Murata T Jpn J Ophthalmol; 2017 Jan; 61(1):51-60. PubMed ID: 27730425 [TBL] [Abstract][Full Text] [Related]
13. Practical Lessons from Protocol I for the Management of Diabetic Macular Edema. Mukkamala L; Bhagat N; Zarbin MA Dev Ophthalmol; 2017; 60():91-108. PubMed ID: 28427069 [TBL] [Abstract][Full Text] [Related]
14. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC; Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896 [TBL] [Abstract][Full Text] [Related]
16. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy. Mikhail M; Stewart S; Seow F; Hogg R; Lois N Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188 [TBL] [Abstract][Full Text] [Related]
17. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema. Cicinelli MV; Cavalleri M; Querques L; Rabiolo A; Bandello F; Querques G Br J Ophthalmol; 2017 Dec; 101(12):1689-1693. PubMed ID: 28432109 [TBL] [Abstract][Full Text] [Related]